270 related articles for article (PubMed ID: 16643608)
21. Electrophoretic separation and characterization of urinary glycosaminoglycans and their roles in urolithiasis.
Gohel MD; Shum DK; Tam PC
Carbohydr Res; 2007 Jan; 342(1):79-86. PubMed ID: 17145044
[TBL] [Abstract][Full Text] [Related]
22. Effects of urinary macromolecules on the nucleation of calcium oxalate in idiopathic stone formers and healthy controls.
Borghi L; Meschi T; Guerra A; Bergamaschi E; Mutti A; Novarini A
Clin Chim Acta; 1995 Jul; 239(1):1-11. PubMed ID: 7586581
[TBL] [Abstract][Full Text] [Related]
23. The relationship of 3' vitamin D receptor haplotypes to urinary supersaturation of calcium oxalate salts and to age at onset and familial prevalence of nephrolithiasis.
Mossetti G; Rendina D; Viceconti R; Manno G; Guadagno V; Strazzullo P; Nunziata V
Nephrol Dial Transplant; 2004 Sep; 19(9):2259-65. PubMed ID: 15213319
[TBL] [Abstract][Full Text] [Related]
24. Hyperoxaluria in idiopathic calcium nephrolithiasis--what are the limits?
Osther PJ
Scand J Urol Nephrol; 1999 Dec; 33(6):368-71. PubMed ID: 10636575
[TBL] [Abstract][Full Text] [Related]
25. Urinary metabolic evaluations in solitary and recurrent stone forming children.
DeFoor W; Minevich E; Jackson E; Reddy P; Clark C; Sheldon C; Asplin J
J Urol; 2008 Jun; 179(6):2369-72. PubMed ID: 18433777
[TBL] [Abstract][Full Text] [Related]
26. Why does the Bonn Risk Index discriminate between calcium oxalate stone formers and healthy controls?
Kavanagh JP; Laube N
J Urol; 2006 Feb; 175(2):766-70. PubMed ID: 16407047
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of calcium oxalate renal stone formation and renal tubular cell injury.
Tsujihata M
Int J Urol; 2008 Feb; 15(2):115-20. PubMed ID: 18269444
[TBL] [Abstract][Full Text] [Related]
28. [Future perspective on the prevention of nephrolithiasis].
Kohjimoto Y; Shinka T; Morimoto S; Nishihata M
Hinyokika Kiyo; 2004 Aug; 50(8):591-6. PubMed ID: 15471083
[TBL] [Abstract][Full Text] [Related]
29. [Plasma oxalate concentration in calcium oxalate stone formers].
Hoshina A
Hinyokika Kiyo; 1984 Oct; 30(10):1405-15. PubMed ID: 6524552
[TBL] [Abstract][Full Text] [Related]
30. Oxalate: from crystal formation to crystal retention.
Koul HK; Koul S; Fu S; Santosham V; Seikhon A; Menon M
J Am Soc Nephrol; 1999 Nov; 10 Suppl 14():S417-21. PubMed ID: 10541276
[TBL] [Abstract][Full Text] [Related]
31. Whole urinary proteins coat calcium oxalate monohydrate crystals to greatly decrease their adhesion to renal cells.
Kumar V; Farell G; Lieske JC
J Urol; 2003 Jul; 170(1):221-5. PubMed ID: 12796693
[TBL] [Abstract][Full Text] [Related]
32. Stabilization of calcium oxalate suspension by urinary macromolecules, probably an efficient protection from stone formation.
Baumann JM; Affolter B; Caprez U; Clivaz C; Glück Z; Weber R
Urol Int; 2007; 79(3):267-72. PubMed ID: 17940361
[TBL] [Abstract][Full Text] [Related]
33. Hepatocyte growth factor has protective effects on crystal-cell interaction and crystal deposits.
Tei N; Tsujihata M; Tsujikawa K; Yoshimura K; Nonomura N; Okuyama A
Urology; 2006 Apr; 67(4):864-9. PubMed ID: 16600342
[TBL] [Abstract][Full Text] [Related]
34. Renal intratubular crystals and hyaluronan staining occur in stone formers with bypass surgery but not with idiopathic calcium oxalate stones.
Evan AP; Coe FL; Gillen D; Lingeman JE; Bledsoe S; Worcester EM
Anat Rec (Hoboken); 2008 Mar; 291(3):325-34. PubMed ID: 18286613
[TBL] [Abstract][Full Text] [Related]
35. Effect of high and low calcium diets on stone forming risk during liberal oxalate intake.
Matsumoto ED; Heller HJ; Adams-Huet B; Brinkley LJ; Pak CY; Pearle MS
J Urol; 2006 Jul; 176(1):132-6. PubMed ID: 16753387
[TBL] [Abstract][Full Text] [Related]
36. Urinary macromolecular inhibition of crystal adhesion to renal epithelial cells is impaired in male stone formers.
Kumar V; Peña de la Vega L; Farell G; Lieske JC
Kidney Int; 2005 Oct; 68(4):1784-92. PubMed ID: 16164655
[TBL] [Abstract][Full Text] [Related]
37. Differential expression of urinary inter-alpha-trypsin inhibitor trimers and dimers in normal compared to active calcium oxalate stone forming men.
Marengo SR; Resnick MI; Yang L; Chung JY
J Urol; 1998 May; 159(5):1444-50. PubMed ID: 9554330
[TBL] [Abstract][Full Text] [Related]
38. Phosphate metabolism in renal stone formers. (I): Indices of phosphate handling in calcium stone patients and healthy subjects.
Wikström B; Backman U; Danielson BG; Fellström B; Hellsing K; Johansson G; Ljunghall S
Scand J Urol Nephrol Suppl; 1981; 61():I:1-18. PubMed ID: 6947410
[TBL] [Abstract][Full Text] [Related]
39. Renal tubular alteration by crystalluria in stone disease-an experimental study by means of MDCK cells.
Lahme S; Feil G; Strohmaier WL; Bichler KH; Stenzl A
Urol Int; 2004; 72(3):244-51. PubMed ID: 15084771
[TBL] [Abstract][Full Text] [Related]
40. Citrate inhibits growth of residual fragments in an in vitro model of calcium oxalate renal stones.
Chow K; Dixon J; Gilpin S; Kavanagh JP; Rao PN
Kidney Int; 2004 May; 65(5):1724-30. PubMed ID: 15086911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
